Jonathan Sitrin

Jonathan Sitrin has over 15 years of work experience in the biopharmaceutical industry. Jonathan currently holds the role of Director/Principal Scientist II at EpiBiologics since October 2022. Previously, from June 2022 to September 2022, they worked as an Associate Director at Soteria Biotherapeutics.

Prior to these roles, Jonathan spent five years at NGM Biopharmaceuticals, starting as a Scientist II in August 2017 and progressing to a Senior Scientist in January 2021. In their role as Principal Scientist, Immune Oncology from January 2022 to June 2022, they led research efforts focused on discovering and developing new immunotherapies, including leading the NGM438 project.

Before joining NGM Biopharmaceuticals, Jonathan worked at Genentech as a Postdoctoral Research Fellow from October 2014 to August 2017. During that time, they investigated genes associated with autoimmune diseases and discovered new mechanisms of immune regulation.

Jonathan's educational background includes a Ph.D. in Immunology from Harvard University, which they completed from September 2009 to July 2014. Their research at Harvard focused on understanding the mechanisms of immunological tolerance and the role of regulatory T cells in autoimmune diseases. Jonathan developed profiling assays for immune cell characterization and biomarker identification.

Early in their career, Jonathan also gained experience as a Research Intern at Merck in 2007.

Overall, Jonathan Sitrin has a strong background in immunology, with a focus on immune oncology and autoimmune diseases. Jonathan has held various scientific and leadership roles, contributing to the discovery and development of novel therapeutics.

Jonathan Sitrin started their education at Carnegie Mellon University in 2005, where they pursued a Bachelor of Science degree in Biological Sciences. Jonathan completed their undergraduate studies in 2009. In 2009, they joined Harvard University to pursue a Doctor of Philosophy (PhD) degree in Immunology. Jonathan successfully completed their PhD studies in 2014.